Changes of KDIGO and MTX dosing guideline stage using CKD-EPISCr and CKD-EPIcys equations.
| A. Change of KDIGO stage using CKD-EPISCr and CKD-EPIcys equations. | |||||||
|---|---|---|---|---|---|---|---|
| Stage | CKD-EPIcys | ||||||
| 1, n = 249 | 2, n = 134 | 3A, n = 22 | 3B, n = 19 | 4, n = 11 | 5, n = 1 | ||
| CKD-EPISCr | 1, n = 312 | 233 | 78 | 1 | 0 | 0 | 0 |
| 2, n = 102 | 16 | 55 | 21 | 9 | 1 | 0 | |
| 3A, n = 16 | 0 | 1 | 0 | 9 | 6 | 0 | |
| 3B, n = 5 | 0 | 0 | 0 | 1 | 4 | 0 | |
| 4, n = 1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| 5, n = 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| B. Change of MTX dosing guideline stage using CKD-EPISCr and CKD-EPIcys equations. | ||||
|---|---|---|---|---|
| eGFR, mL/min/1.73 m2 | CKD-EPIcys | |||
| < 10, n = 0 | 10-50, n = 38 | > 50, n = 398 | ||
| CKD-EPISCr | < 10, n = 0 | 0 | 0 | 0 |
| 10-50, n = 11 | 0 | 11 | 0 | |
| > 50, n = 425 | 0 | 27 | 398 | |
Values are n. Light gray and dark gray cells indicate change of classification to upward and downward stages, respectively. CKD-EPI: chronic kidney disease epidemiology collaboration; cys: cystatin C; eGFR: estimated glomerular filtration rate; KDIGO: Kidney Disease: Improving Global Outcomes; MTX: methotrexate; SCr: serum creatinine.